compared the efficacy and safety of a basal-bolus insulin regimen with that of sliding-scale regular insulin (SSI) in hospitalized general medical patients with type 2 diabetes. The prospective ...

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

Medically reviewed by Mary Choy, PharmD Type 1 diabetes is a chronic condition caused by an autoimmune reaction, in which your body attacks the cells in your pancreas that make the hormone insulin.

Novo Nordisk said that if approved for use, insulin icodec would reduce the number of basal insulin injections needed per year for type 2 diabetics from 365 to 52, a significant reduction in ...